Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 7Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Healthy Volunteer 1Healthy Adults 1Glioblastoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 9Capecitabine 7durvalumab 6pembrolizumab 4tremelimumab 3S 1 (combination) 3Nivolumab 3AZD 6244 3Ramucirumab 2Fluorouracil 2130-nm albumin-bound paclitaxel 2vandetanib 1trifluridine tipiracil drug combination 1trametinib 1tocilizumab 1titanium silicide 1sacituzumab govitecan 1poly ICLC 1futibatinib 1fludarabine 1cemiplimab 1binimetinib 1aflibercept 1Tegafur 1TAS-116 1Psilocybin 1Peptides 1Oxaliplatin 1NUC-1031 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Biliary Tract Neoplasms × Peptides × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡